29.11.2012 Views

Pharmaceutical Administration and Regulations in Japan - Nihs

Pharmaceutical Administration and Regulations in Japan - Nihs

Pharmaceutical Administration and Regulations in Japan - Nihs

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

3.16 Adverse Drug Reaction (ADR) <strong>and</strong><br />

Infection Report<strong>in</strong>g<br />

When marketers of drugs are <strong>in</strong>formed of<br />

any adverse reactions, <strong>in</strong>fections, etc. as<br />

specified by MHLW ord<strong>in</strong>ance for trial<br />

products or their marketed products, they<br />

must report them to the M<strong>in</strong>ister with<strong>in</strong> the<br />

specified period (Notification No. 0317006<br />

dated March 17, 2005).<br />

As of December 28, 1999, the use of the<br />

<strong>Japan</strong>ese version of ICH MedDRA<br />

(MedDRA/J) was authorized for report<strong>in</strong>g of<br />

adverse drug reactions <strong>and</strong> <strong>in</strong>fectious<br />

diseases <strong>and</strong> its use was enforced on April 1,<br />

2004 (Notification No. 0325001 of the Safety<br />

Division <strong>and</strong> Notification No. 0325032 of the<br />

Evaluation <strong>and</strong> Licens<strong>in</strong>g Division, PMSB<br />

dated March 25, 2004).<br />

S<strong>in</strong>ce October 27, 2003, electronic<br />

adverse drug reaction reports have been<br />

accepted (Notification No. 0828010 of the<br />

Safety Division dated August 28, 2003. Refer<br />

to the follow<strong>in</strong>g site). The reports are<br />

required to be sent to the PMDA from April 1,<br />

2006 (Partial Modification of the<br />

<strong>Pharmaceutical</strong> Affairs Law In accordance<br />

with the Special Corporation Rationalization<br />

Plan dated March 25, 2004).<br />

The f<strong>in</strong>al report of the “Study group on<br />

identification <strong>and</strong> prevention of recurrences<br />

of drug-<strong>in</strong>duced hepatitis” published <strong>in</strong> March<br />

2010 discusses problems <strong>and</strong> future<br />

<strong>Pharmaceutical</strong> <strong>Regulations</strong> <strong>in</strong> <strong>Japan</strong>:<br />

prospects related to the drug adverse event<br />

report<strong>in</strong>g system, pharmacovigilance<br />

programs, <strong>and</strong> the problems of off-label drug<br />

use <strong>and</strong> use of unapproved drugs.<br />

http://www.mhlw.go.jp/sh<strong>in</strong>gi/2010/03/s03<br />

00-1.html<br />

3.17 Dissem<strong>in</strong>ation of Information<br />

Marketers of drugs or medical devices,<br />

wholesalers, marketers or leasers of medical<br />

devices, <strong>and</strong> overseas restrictive approval<br />

holders are asked collect <strong>and</strong> exam<strong>in</strong>e<br />

<strong>in</strong>formation on efficacy, safety, <strong>and</strong> proper<br />

use of drugs <strong>and</strong> medical devices <strong>and</strong> supply<br />

such <strong>in</strong>formation to health professionals such<br />

as physicians <strong>and</strong> pharmacists.<br />

3.18 Measures related to the Law<br />

Concern<strong>in</strong>g Access to Information<br />

Held by Adm<strong>in</strong>istrative Organizations<br />

With the enactment of the Law<br />

Concern<strong>in</strong>g Access to Information Held by<br />

Adm<strong>in</strong>istrative Organizations on April 1,<br />

2000, anyone has the right to request<br />

disclosure of documents reta<strong>in</strong>ed by national<br />

government organizations. This law covers<br />

disclosure of documents reta<strong>in</strong>ed by<br />

government organizations except those<br />

concern<strong>in</strong>g non-disclosable <strong>in</strong>formation such<br />

as <strong>in</strong>formation on <strong>in</strong>dividuals, <strong>in</strong>formation on<br />

corporations, etc. This was partially<br />

amended by Cab<strong>in</strong>et Order No. 371,<br />

2011-3 - 33 -

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!